MX369782B - Formulaciones solidas que contienen omega-3 y resveratrol. - Google Patents

Formulaciones solidas que contienen omega-3 y resveratrol.

Info

Publication number
MX369782B
MX369782B MX2016013189A MX2016013189A MX369782B MX 369782 B MX369782 B MX 369782B MX 2016013189 A MX2016013189 A MX 2016013189A MX 2016013189 A MX2016013189 A MX 2016013189A MX 369782 B MX369782 B MX 369782B
Authority
MX
Mexico
Prior art keywords
resveratrol
omega
formulations containing
solid formulations
containing omega
Prior art date
Application number
MX2016013189A
Other languages
English (en)
Other versions
MX2016013189A (es
Inventor
Giannini Giuseppe
SANTANIELLO Mosé
Original Assignee
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma Spa filed Critical Alfasigma Spa
Publication of MX2016013189A publication Critical patent/MX2016013189A/es
Publication of MX369782B publication Critical patent/MX369782B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)

Abstract

La presente solicitud se refiere en la invención una composición sólida que comprende ácidos grasos poliinsaturados omega-3 (n-3 PUFA), o sus esteres de alquilo o resveratrol, adsorbidos en un sustrato inerte y en donde la recuperación de omega-3 es al menos 96 % después de 6 meses a 25oC. La composición de acuerdo a la presente invención se puede formular como complemento alimenticio o medicamento para prevenir o tratar enfermedades cardiovasculares debidas a trastornos en el metabolismo de los lípidos y a la agregación incrementada de plaquetas; a daños debidos a radicales libres, seleccionados del grupo que consiste de arterosclerosis, cáncer, enfermedad inflamatoria de articulaciones, asmas, diabetes, demencia senil y enfermedad ocular degenerativa; y/o enfermedades virales.
MX2016013189A 2014-06-04 2015-03-26 Formulaciones solidas que contienen omega-3 y resveratrol. MX369782B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14001940.7A EP2952180B1 (en) 2014-06-04 2014-06-04 Solid formulations containing resveratrol and omega-3 polyunsaturated fatty acids (n-3 PUFA)
PCT/EP2015/056530 WO2015185239A1 (en) 2014-06-04 2015-03-26 Solid formulations containing omega-3 and resveratrol

Publications (2)

Publication Number Publication Date
MX2016013189A MX2016013189A (es) 2017-01-16
MX369782B true MX369782B (es) 2019-11-21

Family

ID=50884650

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013189A MX369782B (es) 2014-06-04 2015-03-26 Formulaciones solidas que contienen omega-3 y resveratrol.

Country Status (14)

Country Link
US (1) US20170112791A1 (es)
EP (1) EP2952180B1 (es)
JP (1) JP2017522278A (es)
CN (1) CN106456587B (es)
AU (1) AU2015271278A1 (es)
CA (1) CA2943021A1 (es)
EA (1) EA032762B1 (es)
ES (1) ES2615630T3 (es)
MX (1) MX369782B (es)
PL (1) PL2952180T3 (es)
PT (1) PT2952180T (es)
SI (1) SI2952180T1 (es)
UA (1) UA119174C2 (es)
WO (1) WO2015185239A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551570A4 (en) * 2002-08-14 2008-04-09 Du Pont SOLID FLUID POWDER HAVING A HIGH LIQUID LOAD
ITRM20020562A1 (it) 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
WO2009034124A1 (en) * 2007-09-12 2009-03-19 Novozymes A/S Omega-3 stabilisation towards oxidation
KR101100078B1 (ko) * 2008-03-27 2011-12-29 홉킨스바이오연구센터(주) 관절염 치료를 위한 약제학적 조성물
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
AU2010335077A1 (en) 2009-12-23 2012-06-14 Sigma-Tau Industrie Farmaceutiche Riunite Spa Combination composition useful for treating cardiovascular diseases
US20110244031A1 (en) * 2010-03-31 2011-10-06 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations
IT1400695B1 (it) 2010-06-21 2013-06-28 Labomar S R L Composizioni farmaceutiche e/o nutraceutiche contenenti principi attivi insolubili in acqua e procedimento per ottenerle.
BR112015005008B1 (pt) * 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado

Also Published As

Publication number Publication date
JP2017522278A (ja) 2017-08-10
EA032762B1 (ru) 2019-07-31
CN106456587A (zh) 2017-02-22
CN106456587B (zh) 2020-03-20
EA201692399A1 (ru) 2017-03-31
AU2015271278A1 (en) 2016-11-10
SI2952180T1 (sl) 2017-05-31
UA119174C2 (uk) 2019-05-10
EP2952180B1 (en) 2017-01-25
PT2952180T (pt) 2017-03-02
CA2943021A1 (en) 2015-12-10
WO2015185239A1 (en) 2015-12-10
ES2615630T3 (es) 2017-06-07
EP2952180A1 (en) 2015-12-09
US20170112791A1 (en) 2017-04-27
PL2952180T3 (pl) 2017-05-31
MX2016013189A (es) 2017-01-16

Similar Documents

Publication Publication Date Title
MX2016008270A (es) Lipido que comprende acidos grasos poliinsaturados de cadena larga.
NZ631702A (en) Production of long chain polyunsaturated fatty acids in plant cells
GEP201606568B (en) Compositions for the treatment of neurologic disorders
MX342216B (es) Composiciones de acidos grasos.
IL252482B (en) A process for increasing the stability of a preparation containing omega-6 fatty acids with a large number of unsaturations
WO2016040570A3 (en) Dietary emulsion formulations and methods for using the same
NZ747847A (en) Lipid compositions
MY181997A (en) Preparation and composition of medium chain triglycerides containing substantial amount of lauric acid
BR112018001164A2 (pt) composto de fórmula geral, composição farmacêutica e método para o tratamento de uma doença cardiovascular
WO2014165190A3 (en) Compositions comprising docosapentaenoic acid and methods of use
MX2015007085A (es) Composiciones de acido omega-3 pentanoico y metodos de uso.
MX2021006084A (es) Preparacion que comprende una cepa probiotica y un componente de acido graso poliinsaturado.
WO2012153345A9 (en) Docosahexaenoic acid (dha) as polyunsaturated free fatty acid in its directly compressible powder form and method of isolation thereof
JP2016501249A5 (es)
UA111967C2 (uk) Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання
PH12017500738A1 (en) Feeding algae to cattle at low doses to produce high omega 3 levels in beef
MX369782B (es) Formulaciones solidas que contienen omega-3 y resveratrol.
MX361765B (es) Formulacion homogenea que comprende acido graso poliinsaturado omega-3 y resveratrol para administracion oral.
MX2017004839A (es) Composiciones de acidos grasos monoinsaturados y uso para tratar la ateroesclerosis.
WO2015013678A3 (en) Stable fatty acid compositions
PL3560342T3 (pl) Kompozycje wielonienasyconych kwasów tłuszczowych wzbogacone w dha
EP3370714A4 (en) COMPOSITIONS AND METHODS FOR TREATING FATTY ACID METABOLISM DISORDERS
BR112018070194A2 (pt) composto e composição para uso
EP3099782A4 (en) Factors for the production and accumulation of polyunsaturated fatty acids (pufas) derived from pufa synthases
JP2017516820A5 (es)

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ALFASIGMA S.P.A.

FG Grant or registration